Candriam Luxembourg S.C.A. held its position in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) during the second quarter, Holdings Channel reports. The institutional investor owned 200,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A.’s holdings in Sangamo BioSciences were worth $1,158,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the company. Cannell Peter B & Co Inc increased its position in shares of Sangamo BioSciences by 217.5% in the first quarter. Cannell Peter B & Co Inc now owns 31,750 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 21,750 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Sangamo BioSciences by 140.8% in the second quarter. Nisa Investment Advisors LLC now owns 51,300 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 30,000 shares in the last quarter. Wexford Capital LP bought a new position in shares of Sangamo BioSciences during the first quarter worth $299,000. Spark Investment Management LLC bought a new position in shares of Sangamo BioSciences during the first quarter worth $472,000. Finally, Prudential Financial Inc. bought a new position in shares of Sangamo BioSciences during the first quarter worth $1,384,000. 65.24% of the stock is owned by institutional investors.
Shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) traded down 8.02% on Thursday, reaching $4.36. 1,019,173 shares of the company were exchanged. The company’s 50-day moving average price is $4.55 and its 200 day moving average price is $5.69. Sangamo BioSciences Inc. has a 12 month low of $4.08 and a 12 month high of $9.91. The company’s market cap is $307.89 million.
Sangamo BioSciences (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.14. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.38 million. Sangamo BioSciences had a negative return on equity of 36.08% and a negative net margin of 261.81%. The company’s quarterly revenue was down 56.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.17) earnings per share. On average, equities research analysts expect that Sangamo BioSciences Inc. will post ($1.11) EPS for the current year.
A number of equities analysts have weighed in on SGMO shares. Jefferies Group reaffirmed a “buy” rating and issued a $14.00 target price on shares of Sangamo BioSciences in a research note on Thursday, June 9th. Cowen and Company reissued a “buy” rating on shares of Sangamo BioSciences in a research note on Wednesday, August 10th. Janney Montgomery Scott downgraded shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $15.00 to $8.00 in a research note on Thursday, August 4th. Finally, Zacks Investment Research downgraded shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $15.30.
About Sangamo BioSciences
Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.